BioPharma, Startups

Sirnaomics closes second portion of $47M Series C round for RNA-interference drugs

The firm announced that it closed a $22 million Series C2 round, following a $25 million Series C1 round that it had closed last June, led by Asian investors.


A company developing RNA-interference drugs against cancers and fibrotic diseases has closed its latest round of financing.

Sirnaomics – which is headquartered in Gaithersburg, Maryland, and has locations in China – said Friday that it had closed the second part of its Series C round. The total value of the Series C financing is $47 million, including a $25 million C1 portion closed in June 2018 and the latest C2 portion, worth $22 million. Hong Kong-based CR-CP Life Sciences Fund – itself a joint venture of China Resources Group and Thai conglomerate Charoen Pokphand Group – led the C2 round, while US-based Legend Sky Investment and China-based Rich Yield Capital and Rolling Boulder Investment participated. Yuexiu New Industrial Investment had led the C1 round, with participation from Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.

The company plans to use the money to support its clinical and drug-development technology programs. Its most advanced product candidate is STP705, which is in Phase II development for non-melanoma skin cancer and hypertrophic scar reduction, according to its pipeline page. lists a Phase I/II study of 24 patients for the latter indication, which is stated to be still recruiting patients at a single site in California despite an estimated January 2018 completion date. For non-melanoma skin cancer, the company said in December that it had received Food and Drug Administration clearance to begin the Phase II study.

The company is one of several that has been investigating RNA as a target for the treatment of disease. Another firm in the field is Cambridge, Massachusetts-based Alnylam Pharmaceuticals. Earlier this month, Alnylam and Regeneron Pharmaceuticals formed a $1 billion deal to focused on central nervous system and eye drugs, as well as on two C5-targeting drugs in liver diseases. Alnylam and Regeneron already had an existing partnership around nonalcoholic steatohepatitis, or NASH.

Last August, Alnylam became the first company to win approval for an siRNA drug, Onpattro (patisiran), for hereditary transthyretin-mediated amyloidosis, or hAATR.

Photo: jxfzsy, Getty Images